Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03)
Titel:
Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03)
Auteur:
Bamias, A. Dafni, U. Karadimou, A. Timotheadou, E. Aravantinos, G. Psyrri, A. Xanthakis, I. Tsiatas, M. Koutoulidis, V. Constantinidis, C. Hatzimouratidis, C. Samantas, E. Visvikis, A. Chrisophos, M. Stravodimos, K. Deliveliotis, C. Eleftheraki, A. Pectasides, D. Fountzilas, G. Dimopoulos, M.A.